DaVita Inc.
NYSE:DVAMedical - Care Facilities
+$1.60 today
- Market cap
- $10.18B
- Beta
- 0.91
- P/E (TTM)
- 18.2
- EPS (TTM)
- $11.60
Volume 1.12M
Average 0.84M
DVA Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
DaVita Inc.NYSE: DVA
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue grows in line with its trailing trend
Q2 FY2026 revenue of $3.55B rose 5.2% year over year, behind the +6.4% change in trailing-twelve-month revenue. Sequentially, it rose 4.1% from the prior quarter. Over 3 fiscal years it compounded at +5.5% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 5 analysts of $14.19B (+4.0%) for the fiscal year ending Dec 2026, a slowdown from the +6.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $3.55B+4.1% QoQ
- Last fiscal yearDec 2025
- $13.64B+6.5% YoY
- LTMJun 2026
- $14.01B+6.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +5.2% | +2.8% | -2.3 pp |
| 1 year | +6.5% | +4.0% | -2.4 pp |
| 3-year CAGR | +5.5% | +3.7% | -1.8 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 13.64B USD
- Year-over-year change
- +6.5%
- 4-year CAGR
- +4.1%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.64B | +6.5% |
| FY2024 | 2024-12-31 | 12.82B | +5.6% |
| FY2023 | 2023-12-31 | 12.14B | +4.6% |
| FY2022 | 2022-12-31 | 11.61B | -0.1% |
| FY2021 | 2021-12-31 | 11.62B | — |
Revenue vs competitors
How DVA compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +6.4% is the highest of 3, against a peer median of +2.4%.
- Over three fiscal years its annual growth of +5.5% compares with a peer median of +2.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | €19.43B EUR | -0.5% | +0.4% | |
| LTM Jun 2026 | $14.01B USD | +6.4% | +5.5% | |
| LTM Jun 2026 | $11.47B USD | +5.4% | +3.8% | |
| Peer median (excluding DVA) | — | +2.4% | +2.1% | |
Competitors are the stored peer set for DVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 11.62B | 11.61B | 12.14B | 12.82B | 13.64B |
| Cost of Revenue | 7.97B | 8.21B | 8.32B | 8.6B | 9.96B |
| Gross Profit | 3.65B | 3.4B | 3.82B | 4.22B | 3.68B |
| Gross Margin | 31.4% | 29.3% | 31.5% | 32.9% | 27.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 1.2B | 1.36B | 1.47B | 1.54B | 1.67B |
| Operating Expenses | 1.85B | 2.06B | 2.22B | 2.13B | 1.67B |
| Depreciation & Amortization | 680.62M | 732.6M | 745.44M | 723.86M | 715.35M |
| EBITDA | 2.48B | 2.06B | 2.32B | 2.72B | 2.64B |
| EBITDA Margin | 21.4% | 17.7% | 19.1% | 21.3% | 19.4% |
| Operating Income | 1.8B | 1.34B | 1.6B | 2.09B | 2.01B |
| Operating Margin | 15.5% | 11.5% | 13.2% | 16.3% | 14.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 285.25M | 357.02M | 398.55M | 470.47M | 549.67M |
| Other Income / Expenses | (278.88M) | (372.78M) | (425.69M) | (560.09M) | (663.79M) |
| Income Before Tax | 1.52B | 966.28M | 1.18B | 1.53B | 1.35B |
| Pre-Tax Margin | 13.1% | 8.3% | 9.7% | 11.9% | 9.9% |
| Income Tax Expense | 306.73M | 198.09M | 220.12M | 279.66M | 293.11M |
| Net Income | 978.45M | 560.4M | 691.54M | 936.34M | 746.8M |
| Net Margin | 8.4% | 4.8% | 5.7% | 7.3% | 5.5% |
| EPS (Basic) | 9.30 | 5.88 | 7.62 | 11.02 | 9.72 |
| EPS (Diluted) | 8.90 | 5.71 | 7.42 | 10.73 | 9.51 |
| Weighted Avg Shares | 105.23M | 92.99M | 90.79M | 84.99M | 86.1M |
| Weighted Avg Shares (Diluted) | 109.95M | 95.83M | 93.18M | 87.27M | 88.1M |
DaVita Inc.
NYSE:DVA
Intrinsic Alpha fair value
Locked
Current Price
$161.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.